This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While advanced analytics and AI can unlock unprecedented insights, it’s the thoughtful application of these insights that transforms routine interactions between pharmaceutical representatives and healthcareproviders into lasting relationships.
We cannot change the fact that some patients must take multiple drugs, but we can certainly change how we manage it with careful coordination and communication among healthcareproviders, and personalized medicine practices such as pharmacogenomics.
As multi-billion investment continues to pour into the R&D of future obesity medications, the need for evidence generation of health benefits beyond short-term weight loss will be critical to the decision-making of healthcareproviders and payers. appeared first on MedCity News.
For patients who may be unable to afford the high cost of GLP-1 obesity drugs or are worried about the side effects, it’s important for healthcareproviders to offer education on herbal alternatives and consider these as part of the broader treatment conversation. appeared first on MedCity News.
However, most models are based on an old-fashioned and expensive call centre-based approach that fails to meet the needs of patients and healthcareproviders (HCPs) as consumers. Yet, the healthcare experience is antiquated.
One of the fastest-growing frontiers of healthcare is Digital Therapeutics (DTx), which utilizes clinically tested software to prevent, treat, and manage a growing range of medical conditions. The goal was simple: provide access and focused support to patients remotely while simultaneously relieving overtaxed healthcare facilities.
Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. Innovation Is Expanding, But Healthcare Systems Are Slow to Adapt. Driving scale in a slow-moving healthcare ecosystem is not just a challenge for cell and gene therapies.
healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes. CVS’ bid for Oak Street is in keeping with nearly two decades of evolution toward becoming an integrated payer and provider.
“Streaming video provides life sciences advertisers with an efficient and effective way to reach patients at any stage of treatment and can help advance their patient marketing efforts.” Biopharma marketers are following their audiences and investment in this channel continues to increase.
Ittai Dayan , Co-founder & CEO of Rhino Health , shared how his company is transforming the way healthcare AI solutions are created, adopted and measured. About Impetus Digital Impetus Digital is the spark behind sustained healthcare stakeholder communication, collaboration, education, and insight synthesis.
Global healthcare company AmerisourceBergen has launched a cell and gene therapy (CGT) integration hub. The new system can be integrated with biopharma or provider-facing platforms to enable the exchange of information in real time.
Bryan Johnson Senior Director, Product Management, Compass Prescriber Veeva Systems Paving the Way to Faster Treatment Starts Bryan’s exposure to life sciences started at a young age, watching his father’s career at companies like Johnson & Johnson and emerging biopharmas. As rare diseases affect about 1 in 10 people in the U.S.,
Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017).
As professionals with more than a half-century between us working in biopharma and diagnostics marketing and communications from the corporate (Ayaz Malik) and agency (Sandra Stahl) sides, we believe nurturing multigenerational teams is an especially powerful yet underutilized strategy for our industry. To be sure, steps have been taken.
Ittai Dayan , Co-founder & CEO of Rhino Health , will join Natalie Yeadon , Co-founder & CEO of Impetus Digital , to share how his company is transforming the way healthcare AI solutions are created, adopted and measured. About Impetus Digital. Book a Consultative Demo.
Aimed at patients, caregivers, and healthcareproviders, the tool is a key component of NovoCare’s comprehensive approach to disease education and simplifies the intricate insurance verification process. FINALISTS: Crack the JAK (Scientific Global) Don’t Sweat Inventory Management (Accord Biopharma, Inc. &
Veeva OpenData has one of the most accurate customer reference data sets available in the market and provides access to a wide profile of healthcare professionals and healthcare organisations in Singapore. Veeva OpenData provides trusted customer reference data to help pharmaceutical companies better engage with their customers.
Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most. Customer conversion and product uptake have largely depended upon live interactions between treating physicians and biopharma representatives (e.g., sales, medical science liaisons, etc.).
Through this collaboration, healthcareproviders are able to access clinically relevant heart rhythm analyses and actionable reports via PaceMateLIVE to monitor at-risk patients; identify underlying arrhythmias, including atrial fibrillation (AF); and drive improvements to patient care and clinical outcomes.
AZ’s head of biopharma R&D Mene Pangalos said the new device would help support the use of Tezspire to treat “a broad population of severe asthma patients.” ” It is estimated that there are 2.5 million patients worldwide with severe asthma who are uncontrolled, without any phenotypic and biomarker limitation. .”
healthcare system over $800 billion annually. Collaboration across the entire ecosystem—from policymakers and regulators to healthcareproviders to researchers—is critical for creating an environment where innovation can thrive. Ultimately, women’s healthcare needs are unique and demand tailored solutions.
In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience.
Though 80% of healthcareproviders (HCPs) identified as “rep-accessible” in 2008 (that is, willing to meet with over 70% of the sales reps who try to approach them), that number had decreased to 44% in 2017. Fierce Healthcare. No biopharma or device advertisements appear during the prescribing workflow. References: 1.
Using real world data to analyze LHON dynamics To better understand the dynamics of LHON, including disease prevalence and drug usage in the United States, we analyzed real world data from electronic health records (EHR), claims and pharmacy data from healthcare institutions and providers. The Clarivate U.S.
The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero. PNAS 2022, Vol.
This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. With this in mind, our efforts to reach these people should focus on providing answers, information, and hope—with all the necessary caveats. Many people, cumulatively, are affected.
Through contracting with pharmaceutical and biotech companies, VMS BioMarketing provides clinical educator solutions focused on empowering healthcareproviders and patients through product support, education, and training. Reading time: 4 minutes A patient support network isn’t made up of just doctors or nurses.
Biosimilars: The Future of Affordable Biologic Therapies Biologics are some of the most expensive forms of therapy in modern healthcare. However, there are products that can help bridge the affordability gap created by these biologics, while also providing similar efficacy and safety for patient treatment.
healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. Christopher Silva, Senior Healthcare Research Analyst. Pillo, Senior Healthcare Research Analyst.
Each of their trailblazing efforts result in much more than personal or organization success, it results in better quality of life for patients, better care options for healthcareproviders, and happier and healthier people around the world.” Weiss has also made substantial efforts to give back to the community at large.
DANNY SIGURDSON CEO and Founder Courier Health To effectively engage patients and prescribers to improve overall adherence to prescribed medication regimens, biopharma companies first need the visibility and full context of where a patient stands in their treatment journey. Support healthcareproviders in a real and personal way.
In the pharmaceutical sector, this evolved further with privacycompliant data enrichment, enabling hyper-personalized messaging for healthcareproviders (HCPs). By tracking preferences and behaviors, companies tailored interactions to make them more meaningful and effective.
Manufacturers, healthcareproviders, and consumers alike face the need to quickly adapt. A chance to innovate: Global health impacts our world and there are various stakeholders making choices, from manufacturers to healthcareproviders and patients. Impending change affords an opportunity for innovation.
“HealthCentral has a long history of providing thoroughly researched, engaging content that informs and empowers people with serious illness to live well and thrive,” stated Steve Zatz, MD, Chairman and Chief Executive Officer of HealthCentral Corp.
These computational tools offer novel insights to enable drugging of biological targets that have been undruggable to date and hold immense potential to give scientists, healthcareproviders, and patients the tools to address a variety of cancer types in the most comprehensive way possible.
Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. Regardless of the tactics and strategies employed, I would encourage more biopharma professionals to get personally involved in patient engagement programs. Rishi Kadiwar.
The current legal landscape makes access to medication abortion crucial in protecting as much access to reproductive healthcare as possible and in protecting healthcareproviders’ abilities to do their jobs without fear of prosecution.
Yet, reaching and engaging such niche patient populations and the healthcare professionals (HCPs) who service them can be a challenge. How many touchpoints does the patient have with the healthcare system and which stakeholders do they interact with the most? It all starts with deeply understanding the patient journey.
The future of healthcare will be one where technology doesn’t just serve the industry but genuinely improves the lives of individuals, transforming how we interact with medical data, healthcareproviders, and our personal well-being.
This may lead to therapies and dosing regimes being less suitable for minority populations – and according to Hans Bunschoten, chief strategy officer at clinical research company Cerba Research, part of Cerba Healthcare, this is a major problem. What future developments are you most excited about being part of Cerba Research?
Mario Papillon, CEO of Cerba Research comments: “ This MoU is an important milestone with Teddy Lab which demonstrates our commitment to expand our footprint into new geographic territories and to best support our global biopharma customers in their evolving needs.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content